The Filing Desk

Eton Pharmaceuticals vs Kura Oncology

Eton Pharmaceuticals ETON · Kura Oncology KURA · Pharmaceuticals

Eton Pharmaceuticals reported revenue of $80 million in fiscal 2025, 1.2 times Kura Oncology's $68 million in fiscal 2025. Eton Pharmaceuticals' revenue grew 104.9% in its latest year, and Kura Oncology's grew 25.2%. Eton Pharmaceuticals had an operating margin of -1.1%, against -449.9% at Kura Oncology. Free cash flow was $10 million at Eton Pharmaceuticals and −$71 million at Kura Oncology.

Side by side

Eton PharmaceuticalsKura Oncology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$80M$68M
Revenue growth104.9%25.2%
Revenue growth a year, last 5 years——
Gross margin53.5%—
Operating margin−1.1%−449.9%
Net margin−5.8%−412.9%
Free cash flow$10M−$71M
Free cash flow margin12.8%−104.8%
Return on capital−1.9%—
Net debt to EBITDA1.4x—
Dividends and buybacks$0M$0M
Change in diluted share count3.9%1.8%
Last close$63.93$7.77
P/E at the last close——
Insider trades, last 12 monthssold $25.2 million—
Piotroski F-score4 of 93 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Eton PharmaceuticalsKura Oncology
Operating margin
Percent of revenue
Eton PharmaceuticalsKura Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Eton PharmaceuticalsKura Oncology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Eton Pharmaceuticals and Kura Oncology pages.